Dare Bioscience vs TherapeuticsMD
DARE and TXMD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DARE and TXMD compare
TherapeuticsMD is the larger company, worth 2.0 times as much as Dare Bioscience ($21.4M against $10.6M).
TherapeuticsMD keeps more of each dollar of sales as profit, with a net margin of −6.6% compared with −804% at Dare Bioscience.
TherapeuticsMD scores higher on the StockData Score (12 against 5 for Dare Bioscience), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DARE | TXMD |
|---|---|---|
| Size and price | ||
| Market cap | $10.6M | $21.4M |
| Share price | $0.694 | $1.85 |
| Change, 1 year | −61.9% | 37.0% |
| Change, 5 years | −96.5% | −93.5% |
| Beta (5Y) | 1.40 | 0.66 |
| Employees | 24 | 1 |
| StockData Score | ||
| Total score | 5 | 12 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.8× | 6.5× (better) |
| P/B | – | 0.8× |
| FCF yield | −111% | – |
| Fair value | – | $2.64 |
| Margin of safety | – | 29.9% |
| Growth | ||
| Revenue growth (TTM) | – | 27.8% |
| Revenue growth, 5Y average | – | −45.8% |
| Profitability | ||
| Operating margin | −813% | −121% (better) |
| Net margin | −804% | −6.6% (better) |
| FCF margin | −861% | – |
| Return on equity | – | −0.80% |
| Return on invested capital | – | −15.9% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 0.99 | 3.22 (better) |
| Altman Z-score | −13.50 (better) | −34.19 |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 8.5% | 31.7% |
| Held by insiders | 9.4% | 1.6% |
| Insider net buying, 12 months | – | $14.0K |
| Short interest, % of float | 7.1% | 0.27% |
Go deeper
- DARE stock overview
- DARE income statement
- DARE valuation and score
- TXMD stock overview
- TXMD income statement
- TXMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.